ATyr Pharma Announces Research Study With Stanford Medicine Focusing On Understanding The Basic Mechanisms Of Immunosuppression In Glioblastoma Multiforme
ATyr Pharma Announces Research Study With Stanford Medicine Focusing On Understanding The Basic Mechanisms Of Immunosuppression In Glioblastoma Multiforme
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research agreement with Stanford Medicine. Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study. Dr. Lim's research focuses on understanding the basic mechanisms of immunosuppression in glioblastoma multiforme (GBM).
aTyr Pharma，Inc.(納斯達克:ATYR)(" aTyr "或" 該公司")，一家臨床階段的生物技術公司，從其專有的tRNA合成酶平台中發現和開發首創藥物。今天宣佈，它已與Stanford Medicine簽訂了研究協議。Michael Lim萬.D.，斯坦福醫學院神經外科系主任，將擔任該研究的首席研究員。Lim博士的研究重點是理解幾種型膠質母細胞瘤(GBM)中的免疫抑制基本機制。